US2008009433A1PendingUtilityA1

Use of glp-1 or analogs in treatment of myocardial infarction

59
Assignee: EFENDIC SUADPriority: Aug 30, 1996Filed: Dec 21, 2006Published: Jan 10, 2008
Est. expiryAug 30, 2016(expired)· nominal 20-yr term from priority
Inventors:Suad Efendic
A61P 9/00A61P 3/10A61P 9/10A61P 3/00A61K 38/26A61K 38/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled)  
     
     
         13 . A method for preventing or ameliorating injury to the myocardium following a myocardial infarction wherein an initial injury to the myocardium has occurred due to the myocardial infarction comprising administering to an individual an effective amount of a composition comprising GLP-1, a GLP-1 analog, or a GLP-1 derivative in a pharmaceutical carrier.  
     
     
         14 . The method of  claim 13  wherein the injury to the myocardium is caused by free fatty acid oxidation.  
     
     
         15 . The method of  claim 13  wherein the individual has hyperglycemia.  
     
     
         16 . The method of  claim 13  wherein the individual has abnormal glucose tolerance.  
     
     
         17 . The method of  claim 13  wherein the GLP-1, GLP-1 analog, or GLP-1 derivative is administered during the acute phase of a myocardial infarction.  
     
     
         18 . A method of controlling the metabolic cascade that exacerbates infarct damage comprising administering GLP-1, a GLP-1 analog, or a GLP-1 derivative to a patient in need thereof.  
     
     
         19 . The method of  claim 18  wherein the patient has suffered a myocardial infarction.  
     
     
         20 . The method of  claim 19  wherein the GLP-1, GLP-1 analog, or GLP-1 derivative is administered during the acute phase of a myocardial infarction.  
     
     
         21 . The method of  claim 18  wherein the infarct damage occurs following a period of ischemia.  
     
     
         22 . The method of  claim 18  wherein the patient has hyperglycemia.  
     
     
         23 . The method of  claim 22  wherein the hyperglycemia is caused by a stress response to a myocardial infarction.  
     
     
         24 . The method of  claim 18  wherein the patient has abnormal glucose tolerance.  
     
     
         25 . The method of  claim 24  wherein the abnormal glucose tolerance is caused by a stress response to a myocardial infarction.  
     
     
         26 . A method for preventing or ameliorating damage to non-ischemic myocardium following a myocardial infarction comprising administering GLP-1, a GLP-1 analog, or GLP-1 derivative to a patient in need thereof.  
     
     
         27 . The method of  claim 26  wherein the GLP-1, GLP-1 analog, or GLP-1 derivative is administered during the acute phase of a myocardial infarction.  
     
     
         28 . The method of  claim 26  wherein the patient has hyperglycemia.  
     
     
         29 . The method of  claim 28  wherein the hyperglycemia is caused by a stress response to a myocardial infarction.  
     
     
         30 . The method of  claim 26  wherein the patient has abnormal glucose tolerance.  
     
     
         31 . The method of  claim 30  wherein the abnormal glucose tolerance is caused by a stress response to a myocardial infarction.

Join the waitlist — get patent alerts

Track US2008009433A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.